Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

Preclinically, enasidenib and azacitidine (ENA + AZA) synergistically enhance cell differentiation, and venetoclax (VEN), a small molecule Bcl2 inhibitor (i) is particularly effective in IDH2 mutated acute myeloid leukemia (IDH2(mut)AML). This open label phase II trial enrolled patients (pts) with d...

Descripción completa

Detalles Bibliográficos
Autores principales: Venugopal, Sangeetha, Takahashi, Koichi, Daver, Naval, Maiti, Abhishek, Borthakur, Gautam, Loghavi, Sanam, Short, Nicholas. J., Ohanian, Maro, Masarova, Lucia, Issa, Ghayas, Wang, Xuemei, Carlos, Bueso-Ramos, Yilmaz, Musa, Kadia, Tapan, Andreeff, Michael, Ravandi, Farhad, Konopleva, Marina, Kantarjian, Hagop M., DiNardo, Courtney D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789767/
https://www.ncbi.nlm.nih.gov/pubmed/35078972
http://dx.doi.org/10.1038/s41408-021-00604-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789767/
https://www.ncbi.nlm.nih.gov/pubmed/35078972
http://dx.doi.org/10.1038/s41408-021-00604-2

Ejemplares similares